Gul Chablani, MD
Pediatrics · Rockville, MDNPI 1538246061
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AstraZeneca at 24.8% of the total. Among pediatrics clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Novo Nordisk$700
- Lilly USA, LLC$662
- Pfizer$513
- Merck$367
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,535100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $1,621 |
| AbbVie(2 entities) | 71 | $1,121 |
| Novo Nordisk | 33 | $700 |
| Lilly USA, LLC | 34 | $662 |
| Pfizer | 28 | $513 |
| Merck | 31 | $367 |
| GSK | 16 | $325 |
| Johnson & Johnson | 7 | $152 |
| Exact Sciences | 6 | $138 |
| Bayer | 6 | $123 |
| Amarin Pharma, Inc. | 7 | $114 |
| Astellas Pharma US Inc | 5 | $94 |
| Optinose US, Inc. | 2 | $55 |
| Medtronic | 3 | $54 |
| Eisai Inc. | 3 | $53 |
| Intercept Pharmaceuticals, Inc. | 2 | $45 |
| Phadia US Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Soleno Therapeutics, Inc. | 1 | $33 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Boehringer Ingelheim | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $23 |
| Novartis | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,538 in reported general payments places this provider in the 95th percentile of 1,307 pediatrics providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 149 | $168,470 |
| JanuviaSitagliptin Phosphate | 81 | $86,498 |
| OzempicSemaglutide | 62 | $74,189 |
| FarxigaDapagliflozin Propanediol | 54 | $57,795 |
| EliquisApixaban | 39 | $43,691 |
| TrulicityDulaglutide | 22 | $36,983 |
| XareltoRivaroxaban | 38 | $31,604 |
| LinzessLinaclotide | 31 | $22,991 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $20,994 |
| EntrestoSacubitril/Valsartan | 17 | $19,828 |
| MyrbetriqMirabegron | 18 | $19,232 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,525 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,275 |
| Lopinavir-RitonavirLopinavir/Ritonavir | 13 | $9,227 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $27 | $168,470149 claims |
| MerckJanuvia, Janumet | $367 | $107,493100 claims |
| Novo NordiskOzempic | $700 | $74,18962 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,621 | $66,55266 claims |
| PfizerEliquis | $513 | $43,69139 claims |
| Lilly USA, LLCTrulicity | $662 | $36,98322 claims |
| Johnson & JohnsonXarelto | $152 | $31,60438 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $325 | $27,89659 claims |
| AbbVieLinzess, Synthroid | $1,121 | $25,00154 claims |
| NovartisEntresto | $19 | $19,82817 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $19,23218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,307 pediatrics providers in Maryland.
Other pediatrics in Rockville
- Hari SachsRockville$114K
- Victor AbdowRockville$58K
- John PierceRockville$47K
- Pengxin LinRockville$7K
- Jitendrakumar ModiAnnapolis$149K
- Mary Elizabeth YoungerBaltimore$130K
- Brenda BanwellBaltimore$109K
- Ellen FieldsSilver Spring$68K
- John ThomsonBaltimore$67K
- Carmelo CuffariBaltimore$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.